MX9605829A - Inhibition of attachment of h. influenzae to human cells. - Google Patents

Inhibition of attachment of h. influenzae to human cells.

Info

Publication number
MX9605829A
MX9605829A MX9605829A MX9605829A MX9605829A MX 9605829 A MX9605829 A MX 9605829A MX 9605829 A MX9605829 A MX 9605829A MX 9605829 A MX9605829 A MX 9605829A MX 9605829 A MX9605829 A MX 9605829A
Authority
MX
Mexico
Prior art keywords
human
casein
beta
influenzae
attachment
Prior art date
Application number
MX9605829A
Other languages
Spanish (es)
Other versions
MXPA96005829A (en
Inventor
Pradip Mukerji
Amanda Eun-Yeong Seo
Steven Neal Anderson
Linda Ann Harvey
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/249,584 external-priority patent/US5643880A/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX9605829A publication Critical patent/MX9605829A/en
Publication of MXPA96005829A publication Critical patent/MXPA96005829A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The attachment of H. influenzae to human cells, such as oropharyngeal cells, may be inhibited by native human 'beta'-casein, a recombinant form of human 'beta'-casein, and hydrolysates of both. The human 'beta'-casein or hydrolysate may be contained in a liquid enteral nutritional product such as an infant formula. The enteral nutritional product may be used, for example, in the prevention and treatment of otitis media in infants. The human 'beta'-casein or hydrolysate may also be administered as a throat spray or nasally using drops or a spray.
MXPA/A/1996/005829A 1994-05-26 1995-04-18 Inhibition of the union of h. influenzae to cellulashuma MXPA96005829A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US24955694A 1994-05-26 1994-05-26
US249,556 1994-05-26
US249556 1994-05-26
US08249584 1994-05-26
US08/249,584 US5643880A (en) 1994-05-26 1994-05-26 Product for inhibition of attachment of H. influenzae to human cells
PCT/US1995/003789 WO1995032728A1 (en) 1994-05-26 1995-04-18 Inhibition of attachment of h. influenzae to human cells

Publications (2)

Publication Number Publication Date
MX9605829A true MX9605829A (en) 1998-05-31
MXPA96005829A MXPA96005829A (en) 1998-10-23

Family

ID=

Also Published As

Publication number Publication date
JPH10500101A (en) 1998-01-06
CA2190610A1 (en) 1995-12-07
NZ283281A (en) 2000-07-28
WO1995032728A1 (en) 1995-12-07
AU2129395A (en) 1995-12-21
AU695101B2 (en) 1998-08-06
EP0760673A1 (en) 1997-03-12

Similar Documents

Publication Publication Date Title
EP0614616A3 (en) Composition for treating patients with hepatic disease.
GB2282140B (en) Purified forms of dnase
HU912064D0 (en) Process for the production of aralyphic n-substituted amino-alcane-phosphine acids and medical preparations containing them
GR3035275T3 (en) Protein composition
ZA888461B (en) Azelastine-containing medicaments for application in the nose and/or at the eye
GR3023936T3 (en) Heterocyclic alkylamides, process for their preparation and pharmaceutical compositions containing them
AU7405091A (en) Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients DO NOT SEAL - SEE LETTER DATED 22.03.94
ZA876740B (en) Derivatives of 4,5-dihydrooxazoles,a process for their preparation and their use
MX9803565A (en) A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein.
MX9605829A (en) Inhibition of attachment of h. influenzae to human cells.
AU8230187A (en) N,n'-bis-amino acid-l-cystine-peptide-containing amino acid preparations for oral and parenteral administration
HUT49284A (en) Process for production of medical compositions applicable "in loco" against androgene hairlessness
IL97054A0 (en) Pharmaceutical compositions comprising buspirones for the treatment of sleep apneas
MX9605830A (en) Inhibition of infection of mammalian cells by respiratory syncytial virus.
MX9803568A (en) Product for inhibition of attachment of h. influenzae to human cells.
IL102774A0 (en) Process for the preparation of human protein-containing,readily compatible medicaments for infusion or injection purposes
EP0613375A4 (en) Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof.
NZ329311A (en) use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus
DE3476736D1 (en) Use of an antihypoxidoticum with cerebral and peripheral effect
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
DE3480325D1 (en) Pharmaceutical dosage unit
MX9701979A (en) Inhibition of human rotavirus infection.